VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice
Trinité, Benjamin (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Durr, Eberhard (Merck & Co.. Inc.)
Pons-Grífols, Anna (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
O'Donnell, Gregory (Merck & Co.. Inc.)
Aguilar-Gurrieri, Carmen (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Rodriguez, Silveria (Merck & Co.. Inc.)
Urrea, Víctor (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Tarrés-Freixas, Ferran (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Mane, Joel (Merck & Co.. Inc.)
Ortiz, Raquel (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Rovirosa, Carla (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Zhang, Lan (Merck & Co.. Inc.)
Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)

Date:	2024
Abstract:	Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccines have been long overdue. Structure-based vaccine design created a new momentum in the last decade, and the first RSV vaccines have finally been approved in older adults and pregnant individuals. These vaccines are based on recombinant stabilized pre-fusion F glycoproteins administered as soluble proteins. Multimeric antigenic display could markedly improve immunogenicity and should be evaluated in the next generations of vaccines. Here we tested a new virus like particles-based vaccine platform which utilizes the direct fusion of an immunogen of interest to the structural human immunodeficient virus (HIV) protein Gag to increase its surface density and immunogenicity. We compared, in mice, the immunogenicity of RSV-F or hMPV-F based immunogens delivered either as soluble proteins or displayed on the surface of our VLPs. VLP associated F-proteins showed better immunogenicity and induced superior neutralizing responses. Moreover, when combining both VLP associated and soluble immunogens in a heterologous regimen, VLP-associated immunogens provided added benefits when administered as the prime immunization.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Respiratory syncytial virus ; Human metapneumovirus ; Vaccine ; HIV Gag ; Fusion protein ; Virus lies particles ; Immunogenicity ; Neutralizing antibodies
Published in:	Vaccine, Vol. 42 Núm. 15 (May 2024) , p. 3474-3485, ISSN 1873-2518

DOI: 10.1016/j.vaccine.2024.04.048

12 p, 3.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles